Retatrutide activates GIPR and GCGR , achieving over 20% weight loss in phase 2 trials
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drugnaive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
For adults with type 2 diabetes and established atherosclerotic cardiovascular disease, high cardiovascular risk, chronic kidney disease, or heart failure, guidelines recommend GLP-1 agonists with proven cardiovascular benefit as preferred agents, independent of metformin use or baseline A1C
The SUSTAIN-6 trial found that Ozempic reduced the risk of major cardiovascular events like heart attack, stroke, and cardiovascular death by 26%
Direct injection is the preferred method for expedited results
According to studies, glutathione lowers blood lactic acid levels, which in turn lowers blood pressure